physical urticaria

The definition, diagnostic testing and management of chronic inducible urticarias –The EAACI/GA²LEN/EDF/UNEV 2016 consensus panel recommendations 2016 update and revision

241 Magerl, M., Altrichter, S., Borzova, E., Giménez-Arnau, A., Grattan, C. E. H., Lawlor, F., Mathelier-Fusade, P., Meshkova, R. Y., Zuberbier, T., Metz, M., and Maurer, M.+: The definition, diagnostic testing and management of chronic inducible urticarias –The EAACI/GA²LEN/EDF/UNEV 2016 consensus panel recommendations 2016 update and revision. Allergy 2016: 71; 780-802. IF: 7.36

The definition, diagnostic testing and management of chronic inducible urticarias –The EAACI/GA²LEN/EDF/UNEV 2016 consensus panel recommendations 2016 update and revision Read More »

Positive CD63 basophil activation tests are common in children with chronic spontaneous urticaria and linked to high disease activity

251 Netchiporouk, E., Moreau, L., Rahme, E., Maurer, M. Lejtenyi, D., and Ben-Shoshan, M.+: Positive CD63 basophil activation tests are common in children with chronic spontaneous urticaria and linked to high disease activity. Int. Arch. Allergy Immunol. 2016: 171; 81-88. IF: 2.72

Positive CD63 basophil activation tests are common in children with chronic spontaneous urticaria and linked to high disease activity Read More »

Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence

129. Maurer, M., Metz, M., Brehler, R., Hillen, U., Jakob, T., Mahler, V., Pföhler, C., Staubach, P., Treudler, R., Wedi, B., and Magerl, M.: Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J. Allergy Clin. Immunol. 2018: 141; 638-649. IF: 14.11

r.129

Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence Read More »